Go Pro
NASDAQ:TNGX

Tango Therapeutics Q2 2026 Earnings Report

Tango Therapeutics logo
$21.75 -1.74 (-7.41%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$21.74 -0.02 (-0.07%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tango Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Tango Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.56 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tango Therapeutics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Tango Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tango Therapeutics Earnings Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
Tango Therapeutics Q2 Net Loss Widens
See More Tango Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email.

About Tango Therapeutics

Tango Therapeutics (NASDAQ:TNGX) is a biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities. The company uses genetic screening, functional genomics and drug-discovery technologies to identify cancer-specific dependencies that may be addressed with targeted therapies.

Tango’s research activities center on precision oncology and immuno-oncology, including programs designed to selectively eliminate tumor cells or improve the ability of the immune system to recognize and attack cancer. Its pipeline has included small-molecule drug candidates aimed at genetically defined cancer targets, as well as programs intended to enhance immune-cell activity.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Tango Therapeutics originated from research associated with the Broad Institute of MIT and Harvard. The company has also pursued strategic collaborations, including a major research and development collaboration with Gilead Sciences focused on discovering and developing cancer therapies. Tango is led by President and Chief Executive Officer Barbara Weber, M.D.

View Tango Therapeutics Profile